Company Profile

Wellgen Inc
Profile last edited on: 1/25/19      CAGE: 4KYZ5      UEI:

Business Identifier: Food and pharmaceutical products based on nutrigenomics
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

330 Madison Avenue 6th Floor Suite 665
New York, NY 10017
   (607) 738-0100
Location: Single
Congr. District: 12
County: New York

Public Profile

Wellgen Inc. develops food and pharmaceutical products based on the science of nutrigenomics - the study of the effects of nutrients and dietary substances on gene expression. The company uses tools such as quantitative PCR and microarray analysis to discover foods or dietary substances with distinct health-promoting activity based on their effects on gene expression. Rather than develop drugs that target single genes for therapeutic opportunities, Wellgen focuses on the modulation of multiple genes using products with a history of human food use. The company uses a proprietary gene panel that incorporates a set of genes central to the inflammatory process. Wellgen aims to discover new anti-inflammatory substances, but other applications of the company's nutrigenomic research include treatments for aging, bone and joint health, cardiovascular disease, metabolic diseases, skin disease, and diabetes.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 1 NIH $293,244
Project Title: Controlling Type 2 Diabetes With Proprietary Natural Extracts In Medical Foods
2002 1 NIH $125,342
Project Title: Preclinical Evaluation of Black Tea Extracts

Key People / Management

  Kathleen P Mullinix -- Chief Executive Officer and President

  Laura Philips -- Former CEO, Board Member

  David Evans

  Alexander M Gosslau -- Consulting Scientist

  Shiming Li -- Senior Scientist

  Patricia Lucas-Schnarre -- Vice President, Product Development and Marketing

  Richard C E Morgan -- Chairman of the Board

  Catherine A Segal -- Vice President, Business Development